Clinical Trials

Numerous clinical trials spanning Early Phase 1 through Phase 4 evaluate vandetanib as monotherapy or combination therapy across oncological indications, including medullary and differentiated thyroid, non-small cell lung, renal cell, hepatocellular, and head and neck cancers. Sponsored by industry leaders like Genzyme/Sanofi and AstraZeneca alongside academic networks such as the National Cancer Institute and PrECOG, these studies encompass active, recruiting, completed, terminated, and withdrawn statuses. Notably, completed Phase 2 and Phase 3 research has evaluated non-small cell lung and differentiated thyroid cancers.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04760288 WITHDRAWN
Medullary Thyroid Cancer
Hoffmann-La Roche
 2023-11-30 PHASE3
NCT01582191 COMPLETED
Advanced Malignant Neoplasm; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm; Refractory Malignant Neoplasm
M.D. Anderson Cancer Center
 2012-05-14 PHASE1
NCT06482086 RECRUITING
Locally Advanced Thyroid Gland Carcinoma
West China Hospital
 2021-06-01 PHASE2
NCT04211337 ACTIVE_NOT_RECRUITING
Medullary Thyroid Cancer
Loxo Oncology, Inc.
 2020-02-11 PHASE3
NCT02299999 ACTIVE_NOT_RECRUITING
Metastatic Breast Cancer
UNICANCER
 2014-04-07 PHASE2
NCT02638428 UNKNOWN
Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Relapsed Pediatric AML; Refractory Pediatric AML
Samsung Medical Center
 2015-12 PHASE2
NCT02239952 UNKNOWN
Cancer; High-grade Glioma
Amsterdam UMC, location VUmc
 2014-11
NCT01586624 COMPLETED
Cancer; Non Small Cell Lung Cancer
Cancer Research UK
 2012-01-10 PHASE1
NCT02495103 TERMINATED
Renal Cell Carcinoma; Hereditary Leiomyomatosis; Renal Cell Cancer
National Cancer Institute (NCI)
 2015-08-26 PHASE1; PHASE2
NCT00514046 COMPLETED
Medullary Thyroid Carcinoma; Multiple Endocrine Neoplasia Type 2A; Multiple Endocrine Neoplasia Type 2B
National Cancer Institute (NCI)
 2007-07-20 PHASE1; PHASE2
NCT03630120 TERMINATED
Thyroid Cancer; Thyroid Cancer, Medullary; Differentiated Thyroid Cancer; Papillary Thyroid Cancer; Follicular Thyroid Cancer; Poorly Differentiated Thyroid Gland Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
 2018-08-06 PHASE2
NCT03291379 COMPLETED
Carcinoma, Hepatocellular; Metastatic Colorectal Cancer
Boston Scientific Corporation
 2017-05-17 EARLY_PHASE1
NCT01414426 COMPLETED
Lip and Oral Cavity Squamous Cell Carcinoma; Oral Cavity Verrucous Carcinoma; Precancerous Condition
University of Chicago
 2012-01 PHASE2
NCT02117167 COMPLETED
Non-small Cell Lung Cancer Metastatic
UNICANCER
 2014-04-23 PHASE2
NCT01934335 TERMINATED
Invasive Breast Cancer
Ronald Weigel
 2013-10 PHASE2
NCT02530411 UNKNOWN
Neoplasms
Velindre NHS Trust
 2015-04 PHASE2
NCT01601808 COMPLETED
Pancreatic Cancer
University of Liverpool
 2011-10-10 PHASE2
NCT02013089 UNKNOWN
Gastrointestinal Cancers
Sun Yat-sen University
 2013-12
NCT03291379 Completed
Carcinoma Hepatocellular|Metastatic Colorectal Cancer
Boston Scientific Corporation|Biocompatibles UK Ltd
 2017-05-17 Early Phase 1
NCT02015065 COMPLETED
GIST
National Cancer Institute (NCI)
 2013-12-14 PHASE2
NCT00923247 TERMINATED
Medullary Thyroid Carcinoma
National Cancer Institute (NCI)
 2009-02-19 PHASE1; PHASE2
NCT01941849 WITHDRAWN
Phaeochromocytoma; Paraganglioma
University College, London
 2014-10 PHASE1
NCT01191892 COMPLETED
Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Ureter Cancer; Urethral Cancer
Cardiff University
 2010-06 PHASE2
NCT01876784 COMPLETED
Differentiated Thyroid Cancer
Genzyme, a Sanofi Company
 2013-09-17 PHASE3
NCT02495103 Terminated
Renal Cell Carcinoma|Hereditary Leiomyomatosis|Renal Cell Cancer
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
 2015-08-26 Phase 1|Phase 2
NCT00995007 COMPLETED
Glioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Mixed Oligoastrocytoma
National Cancer Institute (NCI)
 2009-09 PHASE2
NCT02530411 Unknown status
Neoplasms
Velindre NHS Trust|Cancer Research UK|AstraZeneca
 2015-04 Phase 2
NCT00821080 COMPLETED
Glioblastoma
Massachusetts General Hospital
 2008-10 PHASE1
NCT01823068 COMPLETED
Non Small Cell Lung Cancer
Samsung Medical Center
 2014-11-03 PHASE2
NCT00566995 COMPLETED
Renal Cancer; Von Hippel Lindau
National Cancer Institute (NCI)
 2008-02-07 PHASE2
NCT01496313 COMPLETED
Thyroid Cancer
Sanofi
 2012-06-08 PHASE4
NCT02268734 Completed
Metastatic Sporadic Medullary Thyroid Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori Milano
 2014-04 --
NCT00880334 COMPLETED
Transitional Cell Carcinoma; Bladder Cancer
Dana-Farber Cancer Institute
 2006-09 PHASE2
NCT01661179 COMPLETED
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Genzyme, a Sanofi Company
 2012-11 PHASE1; PHASE2
NCT00872989 COMPLETED
Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
SWOG Cancer Research Network
 2010-03 PHASE2
NCT01876784 Completed
Differentiated Thyroid Cancer
Genzyme a Sanofi Company|Sanofi
 2013-09-17 Phase 3
NCT00752986 TERMINATED
Breast Cancer
Genzyme, a Sanofi Company
 2008-12 PHASE2
NCT00441142 COMPLETED
Glioblastoma Multiforme; Gliosarcoma
Patrick Y. Wen, MD
 2007-05-25 PHASE1; PHASE2
NCT01298323 COMPLETED
Locally Advanced or Metastatic Medullary Thyroid Cancer; Medullary Thyroid Cancer
Sanofi
 2011-02-25 PHASE3
NCT01661179 Completed
Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Genzyme a Sanofi Company|Sanofi
 2012-11 Phase 1|Phase 2
NCT00753675 COMPLETED
Biliary Tract Cancer; Gallbladder Cancer; Cancer Of The Extrahepatic Bile Duct; Ampullary Carcinoma
Genzyme, a Sanofi Company
 2008-10 PHASE2
NCT01539655 COMPLETED
Medullary Thyroid Cancer
Sanofi
 2012-02 PHASE1
NCT01561781 COMPLETED
Healthy Volunteers
Sanofi
 2012-03 PHASE1
NCT01544140 COMPLETED
Healthy Volunteers
Sanofi
 2012-04 PHASE1
NCT01551615 COMPLETED
Healthy
Sanofi
 2012-03 PHASE1
NCT00667147 COMPLETED
Solid Tumors
University of Southern California
 2008-03 PHASE1
NCT00996723 COMPLETED
Diffuse Intrinsic Pontine Glioma
St. Jude Children's Research Hospital
 2009-10 PHASE1
NCT00757692 COMPLETED
Prostate Cancer
British Columbia Cancer Agency
 2009-01 PHASE2
NCT00472017 COMPLETED
Brain and Central Nervous System Tumors
St. Jude Children's Research Hospital
 2007-04 PHASE1
NCT00720083 TERMINATED
Head and Neck Cancer
Radiation Therapy Oncology Group
 2008-11 PHASE2
NCT00753714 COMPLETED
Non Small Cell Lung Cancer
Genzyme, a Sanofi Company
 2008-10 PHASE2
NCT00687297 COMPLETED
Lung Cancer; Non Small Cell Lung Cancer
PrECOG, LLC.
 2008-04 PHASE2
NCT01004419 WITHDRAWN
Carcinoma, Non Small Cell Lung
University of Wisconsin, Madison
 2009-11 PHASE1
NCT00659438 COMPLETED
Prostate Cancer
Genzyme, a Sanofi Company
 2008-02 PHASE2
NCT01183559 COMPLETED
Cancer of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Cancer of the Stomach
Fox Chase Cancer Center
 2008-08-07 PHASE1
NCT00660725 COMPLETED
Advanced Incurable Solid Malignancy
Leonard Appleman
 2009-02 PHASE1
NCT00613223 COMPLETED
Gliosarcoma; Glioblastoma
Annick Desjardins
 2008-02 PHASE1
NCT00862836 TERMINATED
Ovarian Cancer
Genzyme, a Sanofi Company
 2009-04 PHASE1; PHASE2
NCT00807170 TERMINATED
Non-small Cell Lung Cancer (NSCLC)
Sanofi
 2009-05 PHASE1
NCT00732745 TERMINATED
Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Case Comprehensive Cancer Center
 2008-10 PHASE1
NCT00734890 COMPLETED
Lung Cancer; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
National Institutes of Health Clinical Center (CC)
 2008-03 PHASE1
NCT01372813 TERMINATED
Advanced Clear Cell Renal Carcinoma
National Cancer Institute (NCI)
 2007-12 PHASE2
NCT00822887 COMPLETED
Malignant Gliomas
University of Colorado, Denver
 2007-03 PHASE1
NCT00532909 COMPLETED
Anal, Colon, and Rectal Cancers; Colorectal Neoplasms; Colon/Rectal Cancer
Branimir Sikic
 2006-07 PHASE1
NCT00686036 TERMINATED
Prostate Cancer
Genzyme, a Sanofi Company
 2008-05 PHASE2
NCT00597116 TERMINATED
Mesothelioma
Genzyme, a Sanofi Company
 2007-12 PHASE2
NCT00601614 WITHDRAWN
Unspecified Adult Solid Tumor, Protocol Specific
Mayo Clinic
 2008-01 PHASE1
NCT00777179 COMPLETED
NSCLC
Genzyme, a Sanofi Company
 2008-10 PHASE2
NCT00537095 COMPLETED
Thyroid Neoplasms
Genzyme, a Sanofi Company
 2007-09-28 PHASE2
NCT00481845 TERMINATED
Breast Cancer
Stanford University
 2008-01 PHASE2
NCT00450138 COMPLETED
Head and Neck Cancer
Sanofi
 2006-12 PHASE1
NCT00404924 COMPLETED
Non-Small-Cell Lung Carcinoma
Genzyme, a Sanofi Company
 2006-11 PHASE3
NCT00937417 WITHDRAWN
Breast Cancer; Head and Neck Cancer; Lung Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
SWOG Cancer Research Network
 2008-09 PHASE1
NCT00410761 COMPLETED
Thyroid Cancer
Genzyme, a Sanofi Company
 2006-11-23 PHASE3
NCT00681798 COMPLETED
Pancreatic Cancer
Sanofi
 2006-07 PHASE1
NCT00683787 TERMINATED
Gastric Cancer
Roswell Park Cancer Institute
 2008-05 PHASE2
NCT00445549 TERMINATED
Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms
National Cancer Institute (NCI)
 2007-01 PHASE2
NCT00508001 COMPLETED
Carcinoma, Hepatocellular
Genzyme, a Sanofi Company
 2007-07 PHASE2
NCT00418886 COMPLETED
Non Small Cell Lung Cancer; Lung Cancer
Genzyme, a Sanofi Company
 2007-01 PHASE3
NCT00364351 COMPLETED
Non Small Cell Lung Cancer
Genzyme, a Sanofi Company
 2006-08 PHASE3
NCT00312377 COMPLETED
Non-small Cell Lung Cancer; Lung Cancer
Genzyme, a Sanofi Company
 2006-05 PHASE3
NCT00496665 COMPLETED
Metastatic Breast Cancer
Dana-Farber Cancer Institute
 2007-07 PHASE1
NCT00500292 COMPLETED
Colorectal; Cancer
Genzyme, a Sanofi Company
 2007-03 PHASE2
NCT00454116 COMPLETED
Colorectal Cancer
Genzyme, a Sanofi Company
 2007-03 PHASE2
NCT00098345 COMPLETED
Thyroid Cancer
Genzyme, a Sanofi Company
 2004-11 PHASE2
NCT00358956 COMPLETED
Thyroid Cancer
Genzyme, a Sanofi Company
 2006-08 PHASE2
NCT00503711 COMPLETED
Advanced Solid, Malignant Tumors
Genzyme, a Sanofi Company
 2006-09 PHASE1
NCT00498797 COMPLETED
Prostate Cancer; Metastatic; Hormone Refractory
Sanofi
 2005-12 PHASE2
NCT00494481 COMPLETED
Advanced Breast Cancer
Genzyme, a Sanofi Company
 2006-01 PHASE2
NCT00252746 COMPLETED
Non Small Cell Lung Carcinoma
Genzyme, a Sanofi Company
 2004-12 PHASE2
NCT00066313 COMPLETED
Lung Cancer
Genzyme, a Sanofi Company
 2003-05 PHASE2
NCT00499850 COMPLETED
Advanced Colorectal Carcinoma
Genzyme, a Sanofi Company
 2005-08 PHASE1
NCT00506051 COMPLETED
Carcinoma; Non-Small Cell Lung; Lung Cancer
Genzyme, a Sanofi Company
 2005-07 PHASE1
NCT00507091 COMPLETED
Metastatic; Colorectal; Adenocarcinoma
Genzyme, a Sanofi Company
 2005-08 PHASE1

(data from https://clinicaltrials.gov, updated on 2024-01-05)

Check the Vandetanib (ZD6474) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Vandetanib functions as a potent tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptors and epidermal growth factor receptor, thereby suppressing receptor autophosphorylation and downstream pro-angiogenic signaling cascades. By promoting cellular apoptosis and elevating reactive oxygen species levels to induce autophagy, this receptor blockade inhibits tumor vascularization and cell proliferation, providing therapeutic relevance in clinical trials for thyroid cancers, non-small cell lung cancer, and renal cell carcinoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.